Differential effects of pegylated IFN-α on hematopoiesis in JAK2-V617F (VF) and JAK2-V617F;Dnmt3a^Δ/Δ (VF;Dm^Δ/Δ) mice. (A) Schematic drawing of the experimental setup for BM transplantations and treatment with pegIFN-α. (B) Time course of body weight (n = 24 mice per group). (C) Time course of blood counts and GFP chimerism of recipient mice (n = 24 mice per group). (D) Spleen weight at terminal workup after 16 weeks of treatment. (E) Frequency and GFP chimerism of VF;GFP or VF;Dm^Δ/Δ;GFP HSPCs in BM at terminal workup after 16 weeks of treatment (n = 15 mice per group). (F) Frequency and GFP chimerism of VF;GFP or VF;Dm^Δ/Δ;GFP HSPCs in spleen at terminal workup after 16 weeks of treatment (n = 15 mice per group). (G) Analysis of the proportions of CD41^hi and CD41^lo subpopulations within the mutant (GFP-positive) LT-HSCs. All data are presented as mean ± standard error of the mean. ANOVA with subsequent Tukey (C,E,F,G) posttest or 1-way ANOVA with subsequent Tukey (D) posttest were used. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. CBC, complete blood count.